137 results on '"Mileshkin, Linda R."'
Search Results
2. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation
3. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
4. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial
5. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
6. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
7. The evolution of molecular management of carcinoma of unknown primary.
8. Evaluating the Utility of 18F-FDG PET/CT in Cancer of Unknown Primary.
9. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
10. Prediction of recurrence risk in endometrial cancer with multimodal deep learning
11. The challenge of improving outcomes in locally advanced cervical cancer
12. HECTOR: multimodal deep learning predicts recurrence risk in endometrial cancer.
13. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, -2 and -3 trials
14. Improving survival from metastatic, recurrent, or persistent cervical cancer
15. Abstract 5695: Deep learning risk prediction model of distant recurrence from H&E endometrial cancer slides
16. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
17. Adjuvant Chemotherapy Following Chemo-Radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-Radiation Alone: The Randomised Phase 3 OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274)
18. 2022-RA-825-ESGO The impact of age on prognosis in women with endometrial cancer: a pooled analysis of the PORTEC-1, -2 and -3 randomised trials
19. 2022-RA-809-ESGO Underlying causes and prognosis of mismatch repair deficiency in endometrial cancer other thanMLH1promoter hypermethylation
20. PEARL: A randomised phase 3 trial of palliative care early in advanced lung cancers (ALTG/TOGA 13/008).
21. Evaluating the utility of fluorine-18 fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET)/ computed tomography (CT) scan in cancer of unknown primary.
22. IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
23. First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors.
24. Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).
25. Cervical Cancer: A Global Health Crisis
26. Interpretable Deep Learning Predicts the Molecular Endometrial Cancer Classification from H&E Images: A Combined Analysis of the Portec Randomized Clinical Trials
27. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).
28. Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.
29. Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).
30. Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.
31. Adjuvant chemotherapy for locally advanced cervical cancer – Authors’ reply
32. NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment.
33. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy
34. HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes
35. Identifying biomarkers to guide immunotherapy treatment of cancer of unknown primary.
36. A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
37. DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).
38. NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment.
39. Combination immunotherapy with ipilimumab and nivolumab in patients with rare gynaecological malignancies.
40. A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.
41. Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years.
42. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1Promoter Hypermethylation
43. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC).
44. Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.
45. A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
46. Paragon (ANZGOG-0903)
47. A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
48. Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.
49. Cervical cancer: A global health crisis
50. Author Correction: Prediction of recurrence risk in endometrial cancer with multimodal deep learning
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.